Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (211-220 of 858) with videos related to

Pageof 86
Sort By:
Advances in Orthopedics|December 19, 2013
Distal Femur Allograft Prosthetic Composite Reconstruction for Short Proximal Femur Segments following Tumor ResectionBryan S Moon, Nathan F Gilbert, Christopher P Cannon, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 19, 2020
The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events?Giuseppe Gargiulo, Christopher P Cannon, Charles Michael Gibson, et al.
The American Journal of Medicine|March 28, 2018
Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE TrialWilliam B White, Simon R Heller, Christopher P Cannon, et al.
Journal of the American College of Cardiology|August 18, 2004
A risk score to estimate the likelihood of coronary artery bypass surgery during the index hospitalization among patients with unstable angina and non-ST-segment elevation myocardial infarctionSaihari Sadanandan, Christopher P Cannon, C Michael Gibson, et al.
The American Journal of Cardiology|June 29, 2002
Comparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I)Sabina A Murphy, C Michael Gibson, Frans Van de Werf, et al.
American Heart Journal|May 3, 2005
Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trialCharles S Smith, Christopher P Cannon, Carolyn H McCabe, et al.
The American Journal of Cardiology|September 18, 2004
Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS)David A Morrow, Marc S Sabatine, Elliott M Antman, et al.
Chest|July 24, 2008
Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Shaun G Goodman, Venu Menon, Christopher P Cannon, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 6, 2009
Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22Kausik K Ray, Christopher P Cannon, Richard Cairns, et al.
Circulation|March 6, 2016
Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular DiseaseGeorge Thanassoulis, Ken Williams, Kathleen Kimler Altobelli, et al.
Pageof 86

Showing results (211-220 of 858) with videos related to

Sort By:
Pageof 86
Advances in Orthopedics|December 19, 2013
Distal Femur Allograft Prosthetic Composite Reconstruction for Short Proximal Femur Segments following Tumor ResectionBryan S Moon, Nathan F Gilbert, Christopher P Cannon, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 19, 2020
The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events?Giuseppe Gargiulo, Christopher P Cannon, Charles Michael Gibson, et al.
The American Journal of Medicine|March 28, 2018
Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE TrialWilliam B White, Simon R Heller, Christopher P Cannon, et al.
Journal of the American College of Cardiology|August 18, 2004
A risk score to estimate the likelihood of coronary artery bypass surgery during the index hospitalization among patients with unstable angina and non-ST-segment elevation myocardial infarctionSaihari Sadanandan, Christopher P Cannon, C Michael Gibson, et al.
The American Journal of Cardiology|June 29, 2002
Comparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I)Sabina A Murphy, C Michael Gibson, Frans Van de Werf, et al.
American Heart Journal|May 3, 2005
Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trialCharles S Smith, Christopher P Cannon, Carolyn H McCabe, et al.
The American Journal of Cardiology|September 18, 2004
Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS)David A Morrow, Marc S Sabatine, Elliott M Antman, et al.
Chest|July 24, 2008
Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Shaun G Goodman, Venu Menon, Christopher P Cannon, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 6, 2009
Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22Kausik K Ray, Christopher P Cannon, Richard Cairns, et al.
Circulation|March 6, 2016
Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular DiseaseGeorge Thanassoulis, Ken Williams, Kathleen Kimler Altobelli, et al.
Pageof 86